Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29985188 | 0.80 | EGFR (0.60) | EGFRPIK3CDPIK3CAALDH1A1FGFR4 | |
| SCHEMBL1771905 | 0.80 | EGFR (0.60) | EGFRPIK3CDPIK3CAALDH1A1FGFR4 | |
| SCHEMBL28801910 | 0.78 | EGFR (0.58) | EGFRPIK3CDPIK3CAALDH1A1FGFR4 | |
| SCHEMBL9776814 | 0.72 | EGFR (0.55) | EGFRMETPIK3CDPIK3CAFGFR4 | |
| SCHEMBL30918007 | 0.72 | EGFR (0.55) | EGFRMETPIK3CDPIK3CAFGFR4 | |
| SCHEMBL27741570 | 0.71 | EGFR (0.51) | EGFRMETPIK3CDPIK3CAFGFR4 | |
| SCHEMBL20109814 | 0.71 | EGFR (0.50) | EGFRMETPIK3CDPIK3CAFGFR4 | |
| SCHEMBL19006104 | 0.71 | EGFR (0.58) | EGFRMETPIK3CDPIK3CAFGFR4 | |
| SCHEMBL18563388 | 0.70 | CYP1A2 (0.42) | ALDH1A1 | |
| SCHEMBL28264115 | 0.70 | EGFR (0.49) | EGFRMETPIK3CDPIK3CAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048223-A1 | WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2020-02-13 | — | — | US | disclosed |
| US-10450300-B2 | Wnt signaling pathway inhibitors and therapeutic applications thereof | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2019-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450300-B2 | Wnt signaling pathway inhibitors and therapeutic applications thereof | WNT1, WNT3A, CTNNB1 | EGFR 530/4885MET 775/4885PIK3CD 668/4885 |
| US-20200048223-A1 | WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | WNT1, WNT3A, CTNNB1 | EGFR 530/4885MET 775/4885PIK3CD 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.